CD79A and plasma cell myeloma: This transgenic TCR recognizes, in the context of MHC class II I-Ed, an Id-peptide derived from the variable region of the immunoglobulin IgA that is secreted by the MHC class II-negative MOPC315 myeloma cells [15], [27] (Figure 1A).